Chi Ming, Dudek Arkadiusz Z, Wind Kenneth P
Department of Medicine, Saint Joseph Hospital/University of Illinois at Chicago, Chicago, IL, USA.
Onkologie. 2012;35(4):210-4. doi: 10.1159/000337416. Epub 2012 Mar 15.
Primary hepatic leiomyosarcoma (LMS) is a rare malignancy of the liver in adults, with variable overall survival (OS). The main purpose of this study was to identify prognostic factors of improved survival. Relevant data were abstracted from MEDLINE, EMBASE, and Academic Search Premiere (ASP), and from the medical records of a patient treated at our institution. Multivariate analysis was conducted by generating Cox proportional hazard ratios. We identified 109 patients with primary hepatic LMS; 95 were included for basic description, and 84 for OS analysis. Median age was 58 years (range 19-86 years), 45.0% of the patients were female, and 21.1% were AJCC stage IV. The primary treatment for all 95 patients was as follows: 61.1% had surgery, 13.7% had chemotherapy, 5.3% had liver transplantation, 2.1% received radiotherapy, and 14.7% were managed conservatively. Median OS was 19 months (range 0-181 months) with 1-, 2-, and 5-year survival rates of 61.2, 41.1, and 14.5%, respectively. In a multivariate analysis, smaller size of the largest hepatic lesion (p = 0.038) and negative resection margin (p = 0.0004) were associated with improved survival. Complete surgical resection with clear margin is necessary to improve survival of patients with primary hepatic LMS.
原发性肝平滑肌肉瘤(LMS)是成人肝脏中一种罕见的恶性肿瘤,总体生存率(OS)各不相同。本研究的主要目的是确定改善生存的预后因素。相关数据从MEDLINE、EMBASE和学术搜索高级版(ASP)以及我们机构治疗的一名患者的病历中提取。通过生成Cox比例风险比进行多变量分析。我们确定了109例原发性肝LMS患者;95例纳入基本描述,84例纳入OS分析。中位年龄为58岁(范围19 - 86岁),45.0%的患者为女性,21.1%为美国癌症联合委员会(AJCC)IV期。所有95例患者的主要治疗情况如下:61.1%接受手术,13.7%接受化疗,5.3%接受肝移植,2.1%接受放疗,14.7%接受保守治疗。中位OS为19个月(范围0 - 181个月),1年、2年和5年生存率分别为61.2%、41.1%和14.5%。在多变量分析中,最大肝脏病变较小(p = 0.038)和手术切缘阴性(p = 0.0004)与生存改善相关。为提高原发性肝LMS患者的生存率,进行切缘清晰的完整手术切除是必要的。